FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2427269624> ?p ?o ?g. }

• W2427269624 abstract "Non-small cell lung cancers (NSCLCs) with activating mutations in the Epidermal Growth Factor Receptor (EGFR) gene are associated with high response rates (70-80%) to EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib and gefitinib, but most acquire resistance over time through numerous mechanisms. In these patients, the cMet pathway is often activated to compensate and provide resistance to the EGFR targeted monotherapy; this activation can occur by MET gene amplification, overexpression of cMet protein, or an increase in the ligand HGF. We have designed a bispecific EGFR-cMet antibody (JNJ-61186372) with multiple mechanisms of action resulting in anti-tumor activity in the EGFR mutant setting, with or without cMet pathway activation. Controlled Fab-arm exchange was used to produce JNJ-61186372, a technique that allows for efficient large-scale preparation of bispecific antibodies with a regular IgG 1 structure. JNJ-61186372 was shown to bind EGFR and cMet and efficiently inhibited ligand-induced phosphorylation of both receptors. In addition to this important mechanism of action, we have engineered the antibody to contain lower than normal fucose levels to increase Fc-dependent effector mechanisms. JNJ-61186372 exhibited antibody dependent cellular cytotoxicity (ADCC) activity in vitro in a range of NSCLC cell lines with EGFR mutations, KRas mutation, and/or amplified MET gene. Furthermore, the low fucose form of JNJ-61186372 demonstrated more effective ADCC activity compared to its normal fucose counterpart. The bispecific JNJ-61186372 antibody showed increased potency (2-3 fold) compared to the combination of monovalent EGFR and monovalent cMet antibodies, demonstrating the beneficial effects of dual targeting in a single molecule. Antibody dependent cell-mediated phagocytosis (ADCP) activity of JNJ-61186372 was also confirmed in vitro. We have also demonstrated that Fc-dependent effector functions contributed to in vivo anti-tumor growth activity of JNJ-61186372, in a xenograft model with EGFR mutations and cMet activation. Our data demonstrate that the bispecific antibody JNJ-61186372, generated using controlled Fab-arm exchange, has in vitro ADCC and ADCP activity in EGFR mutant settings, either with or without cMet pathway activation, and with KRas mutation. In addition, the Fc-dependent effector mechanisms contributed to in vivo anti-tumor efficacy. The dual signaling inhibition of EGFR and cMet pathways by JNJ-61186372, combined with enhanced Fc effector function, may provide multiple mechanisms to combat resistance in EGFR mutant NSCLC patients. Citation Format: Keri L. Soring, Katharine D. Grugan, Randall J. Breszki, Jose Pardinas, Leopoldo Luistro, Barbara Bushey, Joost Neijssen, Paul Parren, Janine Schuurman, Mark Anderson, Ricardo Attar, Matthew V. Lorenzi, Mark Chiu, Sheri Moores. Activity of a bispecific antibody targeting EGFR and cMet with enhanced Fc effector function in EGFR mutant setting with cMet pathway activation. [abstract]. In: Proceedings of the AACR Special Conference: Tumor Immunology and Immunotherapy: A New Chapter; December 1-4, 2014; Orlando, FL. Philadelphia (PA): AACR; Cancer Immunol Res 2015;3(10 Suppl):Abstract nr A11." @default.
• W2427269624 created "2016-06-24" @default.
• W2427269624 creator A5009100845 @default.
• W2427269624 creator A5020407874 @default.
• W2427269624 creator A5031112942 @default.
• W2427269624 creator A5037197542 @default.
• W2427269624 creator A5041156260 @default.
• W2427269624 creator A5047602731 @default.
• W2427269624 creator A5048035121 @default.
• W2427269624 creator A5055127462 @default.
• W2427269624 creator A5055963089 @default.
• W2427269624 creator A5057834540 @default.
• W2427269624 creator A5069729938 @default.
• W2427269624 creator A5084122153 @default.
• W2427269624 creator A5086137134 @default.
• W2427269624 creator A5090843615 @default.
• W2427269624 date "2015-10-01" @default.
• W2427269624 modified "2023-09-26" @default.
• W2427269624 title "Abstract A11: Activity of a bispecific antibody targeting EGFR and cMet with enhanced Fc effector function in EGFR mutant setting with cMet pathway activation" @default.
• W2427269624 doi "https://doi.org/10.1158/2326-6074.tumimm14-a11" @default.
• W2427269624 hasPublicationYear "2015" @default.
• W2427269624 type Work @default.
• W2427269624 sameAs 2427269624 @default.
• W2427269624 citedByCount "0" @default.
• W2427269624 crossrefType "proceedings-article" @default.
• W2427269624 hasAuthorship W2427269624A5009100845 @default.
• W2427269624 hasAuthorship W2427269624A5020407874 @default.
• W2427269624 hasAuthorship W2427269624A5031112942 @default.
• W2427269624 hasAuthorship W2427269624A5037197542 @default.
• W2427269624 hasAuthorship W2427269624A5041156260 @default.
• W2427269624 hasAuthorship W2427269624A5047602731 @default.
• W2427269624 hasAuthorship W2427269624A5048035121 @default.
• W2427269624 hasAuthorship W2427269624A5055127462 @default.
• W2427269624 hasAuthorship W2427269624A5055963089 @default.
• W2427269624 hasAuthorship W2427269624A5057834540 @default.
• W2427269624 hasAuthorship W2427269624A5069729938 @default.
• W2427269624 hasAuthorship W2427269624A5084122153 @default.
• W2427269624 hasAuthorship W2427269624A5086137134 @default.
• W2427269624 hasAuthorship W2427269624A5090843615 @default.
• W2427269624 hasConcept C104317684 @default.
• W2427269624 hasConcept C153911025 @default.
• W2427269624 hasConcept C159654299 @default.
• W2427269624 hasConcept C170493617 @default.
• W2427269624 hasConcept C185592680 @default.
• W2427269624 hasConcept C203014093 @default.
• W2427269624 hasConcept C2778087573 @default.
• W2427269624 hasConcept C2779438470 @default.
• W2427269624 hasConcept C2780580887 @default.
• W2427269624 hasConcept C2781187634 @default.
• W2427269624 hasConcept C40677261 @default.
• W2427269624 hasConcept C42362537 @default.
• W2427269624 hasConcept C501734568 @default.
• W2427269624 hasConcept C502942594 @default.
• W2427269624 hasConcept C51785407 @default.
• W2427269624 hasConcept C542903549 @default.
• W2427269624 hasConcept C55493867 @default.
• W2427269624 hasConcept C86803240 @default.
• W2427269624 hasConceptScore W2427269624C104317684 @default.
• W2427269624 hasConceptScore W2427269624C153911025 @default.
• W2427269624 hasConceptScore W2427269624C159654299 @default.
• W2427269624 hasConceptScore W2427269624C170493617 @default.
• W2427269624 hasConceptScore W2427269624C185592680 @default.
• W2427269624 hasConceptScore W2427269624C203014093 @default.
• W2427269624 hasConceptScore W2427269624C2778087573 @default.
• W2427269624 hasConceptScore W2427269624C2779438470 @default.
• W2427269624 hasConceptScore W2427269624C2780580887 @default.
• W2427269624 hasConceptScore W2427269624C2781187634 @default.
• W2427269624 hasConceptScore W2427269624C40677261 @default.
• W2427269624 hasConceptScore W2427269624C42362537 @default.
• W2427269624 hasConceptScore W2427269624C501734568 @default.
• W2427269624 hasConceptScore W2427269624C502942594 @default.
• W2427269624 hasConceptScore W2427269624C51785407 @default.
• W2427269624 hasConceptScore W2427269624C542903549 @default.
• W2427269624 hasConceptScore W2427269624C55493867 @default.
• W2427269624 hasConceptScore W2427269624C86803240 @default.
• W2427269624 hasLocation W24272696241 @default.
• W2427269624 hasOpenAccess W2427269624 @default.
• W2427269624 hasPrimaryLocation W24272696241 @default.
• W2427269624 hasRelatedWork W1980984439 @default.
• W2427269624 hasRelatedWork W2039178120 @default.
• W2427269624 hasRelatedWork W2064458900 @default.
• W2427269624 hasRelatedWork W2083121015 @default.
• W2427269624 hasRelatedWork W2246555949 @default.
• W2427269624 hasRelatedWork W2312459439 @default.
• W2427269624 hasRelatedWork W2316235576 @default.
• W2427269624 hasRelatedWork W2469467701 @default.
• W2427269624 hasRelatedWork W2502012015 @default.
• W2427269624 hasRelatedWork W2892197301 @default.
• W2427269624 hasRelatedWork W2947479209 @default.
• W2427269624 hasRelatedWork W3024740892 @default.
• W2427269624 hasRelatedWork W3082523025 @default.
• W2427269624 hasRelatedWork W3082535998 @default.
• W2427269624 hasRelatedWork W3083047803 @default.
• W2427269624 hasRelatedWork W3083354965 @default.
• W2427269624 hasRelatedWork W3083371992 @default.
• W2427269624 hasRelatedWork W3179580684 @default.
• W2427269624 hasRelatedWork W3182773320 @default.
• W2427269624 hasRelatedWork W3193522287 @default.
• W2427269624 isParatext "false" @default.
• W2427269624 isRetracted "false" @default.

• next